MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

This study is testing whether adding pembrolizumab (an immunotherapy drug) to the standard BEAM chemotherapy regimen before an autologous stem cell transplant (a procedure using your own stem cells) improves outcomes for people with relapsed Hodgkin lymphoma. **You may be eligible if...** - You are eligible for an autologous stem cell transplant with BEAM conditioning - Your general health and organ function are adequate (KPS greater than 70 or ECOG 1 or better) - If you have hepatitis B or C, it must be well controlled with treatment - If you have HIV, it must be well controlled on antiretroviral therapy **You may NOT be eligible if...** - You have had a grade 2 or higher immune-related side effect from a PD-1 inhibitor (like pembrolizumab or nivolumab) that required stopping treatment or using immune-suppressing drugs - You have active autoimmune disease requiring systemic treatment - You are pregnant Talk to your doctor to see if this trial is right for you.